Last reviewed · How we verify
Torsemide and Spironolactone tablet
Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, while spironolactone is a potassium-sparing diuretic that works by antagonizing the aldosterone receptor.
Torsemide is a loop diuretic that works by inhibiting the sodium-potassium-chloride cotransporter in the ascending limb of the loop of Henle, while spironolactone is a potassium-sparing diuretic that works by antagonizing the aldosterone receptor. Used for Hypertension, Edema.
At a glance
| Generic name | Torsemide and Spironolactone tablet |
|---|---|
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Drug class | Loop diuretic and potassium-sparing diuretic |
| Target | Sodium-potassium-chloride cotransporter (NKCC2) and Aldosterone receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Torsemide increases the excretion of sodium and chloride ions in the urine, leading to increased water excretion and a decrease in blood volume. Spironolactone, on the other hand, blocks the action of aldosterone, a hormone that promotes sodium retention and potassium excretion. This dual mechanism of action allows for effective diuresis and blood pressure reduction.
Approved indications
- Hypertension
- Edema
Common side effects
- Hypokalemia
- Hyponatremia
- Dizziness
- Headache
- Nausea
Key clinical trials
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (PHASE3)
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (PHASE3)
- Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
- Study of Drug Therapy for Pediatric Heart Failure
- Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Torsemide and Spironolactone tablet CI brief — competitive landscape report
- Torsemide and Spironolactone tablet updates RSS · CI watch RSS
- Sarfez Pharmaceuticals, Inc. portfolio CI